Internet-delivered Treatment for Transgender Individuals With Co-occurring Mental Health Problems (IERGD)

Internet-delivered Emotion Regulation Treatment (I-ER GD) for Transgender Adults and Co-occurring Mental Health Problems

This project aims to develop and evaluate if an internet delivered psychological intervention for transgender individuals undergoing assessment for gender dysphoria and a support person, is feasible, acceptable and effective in increasing emotional skills, strengthening a healthy identity development, social support and resilience to current and future mental illness.

In two studies, a psychological treatment for transgender adults (18+) seeking health care for gender dysphoria and a support person (i.e., relative, friend) will be evaluated.

The project will be carried out at a specialized unit for transgender health care (ANOVA) at Karolinska University Hospital

Study Overview

• Status: Completed
• Conditions: Gender Dysphoria; Emotion Regulation; Internet Delivered Treatment
• Intervention / Treatment: Behavioral: IERGD; Other: IER SUPPORT

Detailed Description

There are no psychosocial treatments for young transgender adults seeking treatment for gender dysphoria - psychological distress due to the incongruence between one's assigned sex and one's gender identity. This project aims to develop and evaluate if an internet delivered psychological intervention for individuals undergoing assessment for gender dysphoria and a support person, is feasible, acceptable and effective in increasing emotional skills, strengthening a healthy identity development, social support and resilience to current and future mental illness.

Data and Method: In three studies, a psychological treatment for transgender adults (18+) seeking care for gender dysphoria and a support person (i.e., relative, friend) will be evaluated. Study 1 is a feasibility study (N=40) with pre-, post- and weekly assessments evaluating the intervention's feasibility, credibility, acceptability and preliminary efficacy. Study 2 is a qualitative interview study exploring participants' experience of the intervention.

Plan for project realization: The project will be carried out at a specialized unit for transgender health care (ANOVA) at Karolinska University Hospital, with a large patient recruitment base and extensive experience of clinical studies providing good opportunities for later implementation in regular care.

Relevance: Studies show elevated rates of psychopathology in transgender adults. It has been suggested that experiences of minority stress, e.g., discrimination, internalized transphobia and gender identity concealment exhausts the ability to regulate negative emotions in an adaptive way. There is a need for treatment and preventive psychological interventions, particularly as the number of young transgender adults seeking gender affirming treatment has increased markedly during the 2000s. This project will lead to increased knowledge about the specific needs of this growing patient group and develop health care in accordance with national guidelines.

• Study Type: Interventional
• Enrollment (Actual): 24
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden, 17176
    • ANOVA, Karolinska University Hospital, Norra Stationsgatan 69, Plan 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients having had an initial assessment at ANOVA for GD between March 2022 and November 2022 and found eligible for a diagnostic assessment period and having been put on a waitlist for continued evaluation.
2. Being at least 18 years of age;
3. Reporting elevated self-perceived psychiatric symptoms (e.g., depression, anxiety, suicidality) or functional impairment (difficulties maintaining school, work or daily routines);
4. Be able to write and read in Swedish; and
5. Have daily access to a computer with internet connection.

Exclusion Criteria:

1. Evidence of active untreated mania, psychosis or other severe psychiatric symptoms that are deemed primary and need treatment;
2. Current and increased suicide risk, such as intrusive suicide thoughts, or current suicide plans, or recent suicide attempt;
3. Current enrollment in another psychological intervention study or currently receiving regular psychological treatment or
4. Less than 6 weeks of stable psychopharmacotherapy if such treatment is ongoing.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: IERGD; I-ER GD is a 10-week intervention directed to the person with GD, provided via the internet with therapist-support. During treatment, participants have an assigned psychologist to interact with and be offered support by, either through feedback on assignments, asynchronous chats or, if needed, by telephone. I-ER GD will focus on increasing adaptive emotion regulation skills, healthy identity development, interpersonal effectiveness skills, coping and building a resilient lifestyle through psychoeducation on gender minority stress, practicing adaptive emotion regulation skills, and reducing emotional and behavioral avoidance.	Behavioral: IERGD; A 10 week behavioral treatment focusing on gender minority stress, maladaptive and adaptive emotion regulation, emotional awareness, the functionality of emotions, interpersonal skills and values and valued actions.
Other: IER SUPPORT; I-ER Support is a 5-week intervention directed to a support person, provided as an optional addition to I-ER GD. I-ER Support is administered in the same manner and in parallel to the I-ER GD intervention. Treatment content is based on the same principles as I-ER GD, but from the perspective of increasing emotional support and understanding of GD. The support person could benefit from increased coping and emotion regulation skills, as they may also be exposed to discrimination or stigma due to having a transgender child, sibling or loved one. In better understanding the processes of being stigmatized and with improved emotion regulation skills, the support person may offer better support and help alleviate burdening effects for the individual with GD. For this reason, I-ER support is primarily aimed at people without trans-experience.	Other: IER SUPPORT; A 5-week behavioral course for a designated support person (family, friend, other) to the person with GD. The course focuses on teachings on living with minority stress, maladaptive and adaptive emotion regulation, emotional awareness, validation, interpersonal skills and values.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants recruited to I-ER GD.	Measures will include recruitment rate during study inclusion period (0-30 participants).	At pretreatment.
Client Satisfaction Questionnaire (CSQ-8; Attkisson & Zwick, 1982) in I-ER GD	Measures treatment satisfaction after treatment. Range 8-32, higher values equals higher satisfaction with treatment.	At post-treatment (week 12).
The Credibility and Expectancy Questionnaire (Devilly & Borkovec, 2000) in I-ER GD.	Measures treatment credibility and expectancy for positive change. Range 0-5, higher values equals higher treatment credibility and expectancy.	At treatment week 2.
The Negative effects Questionnaire (NEQ; Rozental et al. 2016) in I-ER GD.	Measures negative effects of psychological treatment after an intervention. Range 0-20, higher values equals worse outcomes, and more negative effects of treatment.	At post-treatment (week 12).
The internet intervention Patient Adherence Scale (iiPAS; Lenhard et al. 2019) in I-ER GD	Measures adherence to treatment at two timepoints of the treatment. Range 0-20. Higher scores indicate better adherence.	At mid-treatment (week 5).
The internet intervention Patient Adherence Scale (iiPAS; Lenhard et al. 2019) in I-ER GD	Measures adherence to treatment at two timepoints of the treatment. Range 0-20. Higher scores indicate better adherence.	At post-treatment (week 12).
Number of participants recruited to I-ER SUPPORT.	Measures will include recruitment rate during study inclusion period (0-15 participants).	At pretreatment.
The Client Satisfaction Questionnaire (CSQ-8; Attkisson & Zwick, 1982) in I-ER SUPPORT	Measures treatment satisfaction. Range 8-32, higher values equals higher satisfaction with treatment.	At post-treatment (week 10).
The Credibility and Expectancy Questionnaire (Devilly & Borkovec, 2000) in I-ER SUPPORT	Measures treatment credibility and expectancy for positive change. Range 0-5, higher values equals higher treatment credibility and expectancy.	At treatment week 2.
The Negative effects Questionnaire (NEQ; Rozental et al. 2016) in I-ER SUPPORT.	Measures negative effects of psychological treatment. Range 0-20, higher values equals worse outcomes, and more negative effects of treatment.	At post-treatment (week 10).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in Gender minority stress and resilience (GMSR, Testa et al 2014) for I-ER GD.	Changes in the Gender minority stress and resilience scale. Range 0-17 for sub scales Gender related discrimination, rejection, victimization. Higher values represents higher levels of discrimination, rejection, victimization etc. Range 0-164 for sub scales Non-affirmation of gender identity, Internalized transphobia, Pride, Negative expectations for the future, Nondisclosure and Community connectedness. Higher values represents higher levels of whatever the sub scale covers (e.g. pride, internalized transphobia, community connectedness etc).	At pre-treatment and at post treatment (week 12)
Changes in The Difficulties in emotion regulation scale, (DERS-16; Gratz & Roemer, 2004) for I-ER GD.	Changes in the Difficulties in emotion regulation scale, DERS-16. Range 16-80. Lower values equals better outcomes.	At pre-treatment and at post treatment (week 12)
Changes in The Difficulties in emotion regulation scale, (DERS-16; Gratz & Roemer, 2004) for I-ER GD.	Changes in the Difficulties in emotion regulation scale, DERS-16. Range 16-80. Lower values equals better outcomes.	Weekly during the treatment (weeks 1-11)
Changes in The Emotion Regulation Questionnaire, (ERQ; Gross & John, 2003) for I-ER GD.	Changes in the Emotion Regulation Questionnaire, ERQ. Subscales Cognitive reappraisal (Range 6-42). and Suppression (Range 4-28). Higher values equals better outcomes in reappraisal, and worse outcomes in Suppression.	At pre-treatment and at post treatment (week 12)
Changes inThe Alcohol Use Disorders Identification Test (AUDIT; Berman, Wennberg & Källmén, 2012) for I-ER GD.	Changes in alcohol consumption. Range 0-40 where higher values equal higher substance use, worse outcomes.	At baseline and at post treatment (week 12)
Changes inThe Drug Use Disorders Identification Test (DUDIT; Berman, Wennberg & Källmén, 2012) for I-ER GD.	Changes in drug consumption. Range 0-44 where higher values equal higher substance use, worse outcomes.	At baseline and at post treatment (week 12)
Changes in Gender Congruence and Life Satisfaction Scale (GCLS; Dhejne et al. 2019) for I-ER GD	Change and measure improvements in gender (in)congruence, related mental well-being, and life satisfaction throughout the process of undergoing gender affirming medical interventions. Range: 38-190 where higher values indicate greater gender congruence, greater gender-related well-being, and greater life satisfaction.	At baseline and at post treatment (week 12)
Changes in Work and social adjustment scale (WSAS; Marks 1986) for I-ER GD	Changes in functioning. Ranges from 0-40 where higher scores indicate a more impaired functioning.	At baseline and at post treatment (week 12)
Changes in Social Interaction Anxiety Scale (SIAS; Mattick & Clarke 1998) for I-ER GD	Changes in anxiety over 20 different situations. Ranges from 0-80 where higher scores indicate a higher social anxiety.	At pre-treatment and at post treatment (week 12)
Changes in Social Interaction Anxiety Scale (SIAS; Mattick & Clarke 1998) for I-ER GD	Changes in anxiety over 20 different situations. Ranges from 0-80 where higher scores indicate a higher social anxiety.	Weekly during the treatment (weeks 1-11)
Changes in Montgomery Åsberg Depression Rating Scale (MADRS-S; Montgomery & Åsberg 1979) for I-ER GD	Changes in depressive symptoms. Ranges from 0-54 where higher scores indicate higher depressive severity.	At pre-treatment and post treatment (week 12)
Changes in Deliberate Self-Harm Inventory (DSHI-9; Lundh, Karim & Quillisch 2007) for I-ER GD	Changes in instances and forms of self-harming behavior. Higher number of instances indicates worse outcomes.	At pre-treatment and at post treatment (week 12)
Changes in Deliberate Self-Harm Inventory (DSHI-9; Lundh, Karim & Quillisch 2007) for I-ER GD	Changes in instances and forms of self-harming behavior. Higher number of instances indicates worse outcomes.	Weekly during the treatment (weeks 1-11)
Changes in Brunnsviken Brief Quality of Life Inventory (BBQ; Lindner et al, 2016) for I-ER GD	Changes in perceived quality of life. Range: 0-96. Higher scores indicate a higher perceived quality of life.	At pre-treatment and at post treatment (week 12)
Changes in Satisfaction With Life, Swedish (SWLS; Diener 1985) for I-ER GD	Changes in global cognitive judgements of one's life. Range: 0-35. Higher score indicates higher satisfaction with one's life.	At pre-treatment and at post treatment (week 12)
Changes in Perceived Stress Scale (PSS-14; Cohen, Kamarck & Mermelstein 1983) for I-ER GD	Changes in perceived stress. Range: 0-56. Higher scores indicate greater perceived stress.	At pre-treatment and at post treatment (week 12)
Changes in Multidimensional Scale of Perceived Social Support (MSPSS; Zimet et al, 1988) for I-ER GD	Changes in perceived support from family, friends and significant other(s). Range: 12-84. Higher scores indicate greater perceived stress.	At pre-treatment and at post treatment (week 12)
Changes in Rosenberg's scale of self-esteem (Rosenberg; Schmitt & Allik 2005) for I-ER GD	Changes in self-esteem. Range: 0-40. Higher scores indicate higher self-esteem.	At pre-treatment and at post treatment (week 12)
Changes in Rumination Response Scale (RRS-10; Nolen-Hoeksema, Morrow 1991) for I-ER GD	Changes in ruminative tendencies. Range: 10-40. Higher scores indicate higher levels of ruminative response styles.	At pre-treatment and at post treatment (week 12)
Changes in Affect Labeling Questionnaire (ALQ; Sahi et al, in prep.) for I-ER GD	Changes in one's ability to recognize emotions. Range 12-60. Higher scores indicates higher ability to recognize and label emotions.	At pre-treatment and at post treatment (week 12)
Changes in The Gender/Sex diversity belief scale (GSDB; Schudson & van Anders, 2022) for I-ER SUPPORT	Changes in the Gender/Sex diversity belief scale. Range 23-161. Higher values equals more positive attitudes toward transgender individuals.	At pre-treatment and at post treatment (week 10)
Changes in Affect Labeling Questionnaire (ALQ; Sahi et al, in prep.) for I-ER SUPPORT	Changes in one's ability to recognize emotions. Range 12-60. Higher scores indicates higher ability to recognize and label emotions.	At pre-treatment and at post treatment (week 10)
Changes in The Emotion Regulation Questionnaire, (ERQ; Gross & John, 2003) for I-ER SUPPORT.	Changes in the Emotion Regulation Questionnaire, ERQ. Subscales Cognitive reappraisal (Range 6-42). and Suppression (Range 4-28). Higher values equals better outcomes in reappraisal, and worse outcomes in Suppression.	At pre-treatment and at post treatment (week 10)
Changes in The Difficulties in emotion regulation scale, (DERS-16; Gratz & Roemer, 2004) for I-ER SUPPORT	Changes in the Difficulties in emotion regulation scale, DERS-16. Range 16-80. Lower values equals better outcomes.	At pre-treatment and at post treatment (week 10)
Changes in The Difficulties in emotion regulation scale, (DERS-16; Gratz & Roemer, 2004) for I-ER SUPPORT	Changes in the Difficulties in emotion regulation scale, DERS-16. Range 16-80. Lower values equals better outcomes.	Weekly during the treatment (weeks 1-10)

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Investigators: Principal Investigator: Hanna Sahlin, PhD, Karolinska Institutet

Study record dates

Study Major Dates

• Study Start (Actual): August 24, 2022
• Primary Completion (Actual): June 30, 2023
• Study Completion (Actual): June 30, 2023

Study Registration Dates

• First Submitted: August 30, 2022
• First Submitted That Met QC Criteria: September 6, 2022
• First Posted (Actual): September 9, 2022

Study Record Updates

• Last Update Posted (Actual): September 11, 2023
• Last Update Submitted That Met QC Criteria: September 8, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Sexual Dysfunctions, Psychological; Gender Dysphoria
• Other Study ID Numbers: 2022-00577-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No